Lomustine

LOMUSTINE is a type of chemotherapy for treating cancer. Lomustine belongs to a group of medicines known as alkylating agents. Lomustine interferes with cell growth and is used to treat brain tumors and certain cancers of the blood (Hodgkin''s disease). Generic lomustine capsules are not yet available.'

Brands
Adult Dose
Dose: 100 to 130 mg/m2
Single Dose: 120 (115)
Frequency: As recommended.
Route: PO
Instructions: every 6 weeks
Neonatal
Paedriatic
Characteristics
. The Molecular Weight of Lomustine is 233.70.
Contraindications
Lomustine is contraindicated in conditions like Hypersensitivity to any component of product.
Effects
The severe or irreversible adverse effects of Lomustine, which give rise to further complications include Pregnancy.The signs and symptoms that are produced after the acute overdosage of Lomustine include Hypoxaemia, Yellow skin, Sore throat, Liver dysfunction, Bruising, Pulmonary toxicity.The symptomatic adverse reactions produced by Lomustine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Confusion, Lethargy, Hair loss, Nausea and vomiting, Loss of appetite, Confusion, Mouth sores.
Indications
'Lomustine is primarily indicated in conditions like Brain tumors, Hodgkin''s disease, and can also be given in adjunctive therapy as an alternative drug of choice in Breast cancer, Lung cancer, Multiple myeloma, Non-hodgkin''s lymphoma, Non-hodgkin''s lymphoma, Ovarian cancer, Pancreatic cancer, Renal carcinoma.'
Interactions
No data regarding the interactions of Lomustine was found.
Interfrence
Liver Function Test (LFT) Periodic blood countMonitoring of renal function
Risks
Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Tablets Store in a well closed container, Below 40°C.
Warnings
Since the major toxicity is delayed bone marrow suppression, blood counts should be monitored weekly for at least 6 weeks after a dose. Liver and renal function tests should be monitored periodically. For all instances where the use of lomustine is considered for chemotherapy, the physician must evaluate the need and usefulness of the drug against the risks of toxic effects or adverse reactions. Reinstitution of lomustine therapy should be carried out with caution, and with adequate consideration of the further need for the drug and alertness as to possible recurrence of toxicity.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.